GlaxoSmithKline (GSK) Getting Somewhat Favorable News Coverage, Study Finds
Press coverage about GlaxoSmithKline (NYSE:GSK) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. GlaxoSmithKline earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned press coverage about the pharmaceutical company an impact score of 46.603775679157 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- GlaxoSmithKline’s (GSK) “Neutral” Rating Reiterated at JPMorgan Chase & Co. (americanbankingnews.com)
- 5 dividend stocks with strong growth prospects? SSE PLC, BP plc, GlaxoSmithKline plc, British American Tobacco plc … – Investomania (blog) (investomania.co.uk)
- Is GlaxoSmithKline plc a Buy in 2018? | Business Markets and … – Madison.com (host.madison.com)
- GlaxoSmithKline plc isn’t the only Footsie dividend stock I’d buy today (uk.finance.yahoo.com)
GSK has been the topic of a number of research analyst reports. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday, October 24th. Zacks Investment Research lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Investec downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. TheStreet upgraded shares of GlaxoSmithKline from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Finally, Bank of America downgraded shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Thursday, October 26th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have assigned a buy rating to the company’s stock. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus target price of $38.57.
In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The stock was bought at an average price of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 10.00% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: “GlaxoSmithKline (GSK) Getting Somewhat Favorable News Coverage, Study Finds” was first reported by Marea Informative and is the sole property of of Marea Informative. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.mareainformativa.com/2018/01/30/glaxosmithkline-gsk-getting-somewhat-favorable-press-coverage-study-finds-updated-updated-updated.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.